Genocea to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.
Conferences:
| Event: | Longwood Healthcare Leaders Winter Webconference - |
| Topic 1: | Innovation in Cell Therapy |
| Format: | Panel |
| Date: | Thursday, January 6, 2022 |
| Time: | 1:30 PM ET |
| Topic 2: | Making a Big Impact With Limited Resources |
| Format: Date: Time: | Panel Thursday, January 6, 2022 5:10 PM ET |
Event: | LifeSci Partners 11th Annual Corporate Access Event - |
| Topic 1: | Innovative Approaches to Cell Therapy for Oncology |
| Format: | Panel |
| Date: | Friday, January 7, 2022 |
| Time: | 8:30 AM ET |
| Topic 2: | Cancer Vaccines: Promises, Promises … Has Their Day Come? |
| Format: Date: Time: | Panel Friday, January 7, 2022 2:00 PM ET |
| Event: | H.C. Wainwright BIOCONNECT Virtual Conference - |
| Topic: | Corporate Update |
| Format: | On demand presentation |
| Date: | Monday, January 10, 2022 |
| Time: | 7:00 AM ET |
| Event: | Advanced Therapies Week - |
| Topic: | Add It Up: 3 Things to Consider for Capacity Expansion |
| Format: | Panel |
| Date: | Wednesday, January 26, 2022 |
| Time: | 5:00 PM ET |
About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. We have two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy comprising neoantigen-targeted peripheral cells for which we are conducting a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit .
| Investor Contact: | Media Contact: | ||
| Dan Ferry | Sarah O’Connell | ||
| 617-430-7576 | |||
